BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE tablet United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride and naloxone hydrochloride dihydrate tablet

hikma pharmaceuticals usa inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride dihydrate (unii: 5q187997ee) (naloxone - unii:36b82amq7n) - buprenorphine 2 mg - buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. buprenorphine and naloxone sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)]. risk summary the data on use of buprenorphine, one of the active ingredients in buprenorphine and naloxone sublingual tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data ]. observational studies have reported on congenita

BUPRENORPHINE HYDROCHLORIDE tablet United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride tablet

tya pharmaceuticals - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 2 mg - buprenorphine hcl sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. buprenorphine hcl sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. under the drug addiction treatment act (data) codified at 21 u.s.c. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the secretary of health and human services (hhs) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. buprenorphine hcl sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been

Temgesic 0.3 mg/ml inj. sol. i.v./i.m. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

temgesic 0.3 mg/ml inj. sol. i.v./i.m. amp.

eumedica pharmaceuticals gmbh - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine

Buprecare 0,3 mg/ml inj. sol. i.m. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

buprecare 0,3 mg/ml inj. sol. i.m. amp.

ecuphar sa-nv - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; cat

Bupredine Multidose 0,3 mg/ml inj. sol. i.v./i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bupredine multidose 0,3 mg/ml inj. sol. i.v./i.m. vial

le vet. (beheer) b.v. - buprenorphine hydrochloride 0,324 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.324 mg/ml - buprenorphine - horse; dog; cat

Buprenodale Multidose 0,3 mg/ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

buprenodale multidose 0,3 mg/ml inj. sol. i.m./i.v. vial

dechra regulatory b.v. - buprenorphine hydrochloride 0,324 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; horse; cat

Vetergesic Multidosis 0,3 mg/ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vetergesic multidosis 0,3 mg/ml inj. sol. i.m./i.v. vial

ceva santé animale sa-nv - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine - dog; cat

BUPRENORPHINE HYDROCHLORIDE- buprenorphine hydrochloride tablet United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride- buprenorphine hydrochloride tablet

lake erie medical dba quality care products llc - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 8 mg - buprenorphine sublingual tablets is indicated for the treatment of opioid dependence and is preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. under the drug addiction treatment act (data) codified at 21 u.s.c. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the secretary of health and human services (hhs) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. buprenorphine sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported. [see warnings and precautions (5.8)]. pregnancy category c risk summary there are no adequate

BUPRENORPHINE HYDROCHLORIDE injection United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride injection

par pharmaceutical, inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 0.324 mg in 1 ml - buprenorphine hydrochloride injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings: addiction, abuse, and misuse] reserve buprenorphine for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. buprenorphine hydrochloride is contraindicated in patients with: - significant respiratory depression [see warnings]. significant respiratory depression [see warnings]. - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. acute or severe bronchial asthma i

BUPRENORPHINE HYDROCHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

buprenorphine hydrochloride injection, solution

american regent, inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 0.324 mg in 1 ml - buprenorphine hydrochloride injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings: addiction, abuse, and misuse] reserve buprenorphine hydrochloride injection for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. buprenorphine hydrochloride injection is contraindicated in patients with: - significant respiratory depression [see warnings]. significant respiratory depression [see warnings]. - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings